MYGN
Myriad Genetics·NASDAQ
--
--(--)
--
--(--)
4.59 / 10
Netural
Capital flow assessment yields 7.63/10, denoting robust fund flow characteristics. Strengths in overall, block, Medium, Large, and Extra-large trends confront pressures from Small patterns, resulting in positive liquidity outlook. Analyst coverage indicates cautiously optimistic analyst perspective with balanced view. Rating distribution: Buy(25.0%), Neutral(75.0%) among 4 analysts, supported by 1.55 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
25%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-05
InstitutionWells Fargo
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for MYGN?
- MYGN holds a Bearish analyst rating, with 25% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.59/10 (Netural).
